144-Hour Visa-Free Transit Unlocks Wonders of Yunnan: "Yunnan: A Many-Splendored Life" Awaits You
21.10.2024 03:00:00 CEST | Business Wire | Press release
With the expansion of China's 144-hour visa-free transit policy, Yunnan Province has opened its doors wider to international travelers, extending to include Kunming, Lijiang, Yuxi, Pu'er, Chuxiong, Dali, Xishuangbanna, Honghe, Wenshan, and nine other cities and prefectures. Travelers from 54 countries can enter Yunnan through Kunming Changshui International Airport, Lijiang Sanyi International Airport, and Mohan Railway Port by presenting valid international travel documents and onward tickets within 144 hours. This allows for a spontaneous Yunnan tour without cumbersome visa processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241020373774/en/
Countries Eligible for the 144-Hour Visa-Free Transit Policy in Yunnan Province (Graphic: Business Wire)
"Yunnan: A Many-Splendored Life" is a lifestyle with fantastic nature and great ecosystems. Yunnan boasts three World Natural Heritage Sites – Three Parallel Rivers, Chengjiang Fossil Site, and Yunnan Stone Forest. Snow-capped plateaus stand alongside peaks and canyons, complemented by rivers, lakes, and forests, to create a magnificent scenery. Yunnan is known as a blooming "Spring City": camellias grace Dali, flamboyant flowers brighten Xishuangbanna, Ottelia acuminata sways on Lugu Lake, and winter cherry blossoms adorn Wuliang Mountain. Kunming Dounan Flower Market allows travelers to take a piece of Yunnan's spring home. Yunnan is also home to rare animal species like Yunnan snub-nosed monkeys, Asian elephants, and black-headed gulls.
"Yunnan: A Many-Splendored Life" is a lifestyle with profound culture. Yunnan boasts three World Cultural Heritage Sites – Lijiang Old Town, Honghe Hani Rice Terraces, and Jingmai Mountain Ancient Tea Forests in Pu'er, and eight National Famous Historical and Cultural Cities. Historical corridors like Southern Silk Road and Tea Horse Road reflect Yunnan's foreign trade and cultural exchanges. The Bai's Three-Course Tea, the Naxi's Dongba culture and pictographs, the Yi's Torch Festival, and the Dai's Water-Splashing Festival and Peacock Dance highlight its vast cultural legacy.
"Yunnan: A Many-Splendored Life" is a green and healthy lifestyle. Yunnan is an ideal destination for wellness tourism, outdoor activities, and international sports events, with lush mountains, clear waters, and spring-like climate year-round. Eco-friendly products, including Yunnan's flowers, tea, fruits, vegetables, medicinal herbs, and coffee, along with dishes like Mushroom feasts, Yunnan ham, cross-bridge rice noodles, flower cakes, and steam pot chicken, create unforgettable memories.
Yunnan offers boundless natural beauty, a warm living atmosphere, and a healthy lifestyle. As the 144-hour visa-free travelers swarm in, Yunnan will extend greater hospitality and invite them to experience its unique charm and beauty.
Video link:
https://youtu.be/IIdperTx2EA?si=KsT_M88yNRHwJe26
View source version on businesswire.com: https://www.businesswire.com/news/home/20241020373774/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom